EFFECT OF BLOOD PRESSURE – LOWERING DRUGS IN HEART FAILURE: A SYSTEMATIC REVIEW
Keywords:
Antihypertension, Blood Pressure, Cardiovascular Disease, Heart FailureAbstract
It is probable that hypertension is the most major and influential risk factor that can be addressed to avoid the development of heart failure. The development of hypertensive heart disease is the end result of persistently elevated blood pressure, which causes remodeling of the heart's left ventricle. Heart failure is the inevitable manifestation of this condition. The early detection of cardiovascular illness and therapy that is adapted to the specific requirements of the patient are both critical components of an efficient preventative plan for cardiovascular disease. According to a study, certain types of antihypertensive medicine can reduce the progression of hypertension to heart failure (HF), but not all of these treatments are equally as efficient as one another in achieving this goal. Patients should try to avoid taking modest dosages of hydrochlorothiazide once per day, as this is the recommended course of treatment. When it comes to the prevention of heart failure, however, it would appear that long-acting thiazide-type diuretics like chlorthalidone and indapamide have an edge over other hypertension medications. This article presents good data to support the idea that individual patients can benefit from additional reductions in blood pressure even if they are already at or below a certain blood pressure guideline target. It is especially critical for those who are at the highest cardiovascular risk to achieve this decrease (eg, patients with diabetes who are smokers).
References
Loscalzo J. Harrison’s Cardiovascular Medicine. Philadelphia: McGraw-Hill Education; 2012.
National Cancer Institute. NCI Dictionary of Cancer Terms [Internet] NCI Dictionary. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/chronic-heart-failure
Di Palo KE, Barone NJ. Hypertension and Heart Failure: Prevention, Targets, and Treatment. Heart Fail Clin. 2020 Jan;16(1):99–106.
Pfeffer MA. Heart Failure and Hypertension: Importance of Prevention. Med Clin North Am. 2017 Jan;101(1):19– 28.
Laurent S, Boutouyrie P. Blood pressure lowering trials: wrapping up the topic? Lancet [Internet] 2016;387(10022):923–4. Available from: https://www.sciencedirect.com/science/article/pii/S0140673615013446
Bavishi C, Messerli FH, Kadosh B, Ruilope LM, Kario K. Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. Eur Heart J. 2015;36(30):1967–73.
Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, et al. The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003 Mar;24(5):442–63.
Truby LK, Rogers JG. Advanced Heart Failure: Epidemiology, Diagnosis, and Therapeutic Approaches. JACC Heart Fail. 2020 Jul;8(7):523–36.
Messerli FH, Rimoldi SF, Bangalore S. The Transition From Hypertension to Heart Failure: Contemporary Update. JACC Hear Fail [Internet] 2017;5(8):543–51. Available from: https://www.sciencedirect.com/science/article/ pii/S2213177917303177
Nagueh SF. Heart failure with preserved ejection fraction: insights into diagnosis and pathophysiology. Cardiovasc Res. 2021 Mar;117(4):999–1014.
Kotecha D, Manzano L, Krum H, Rosano G, Holmes J, Altman DG, et al. Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data metaanalysis. bmj. 2016;353.
Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. N Engl J Med. 2021 Sep;385(14):1268–79.
Hermida RC, Crespo JJ, Domínguez-Sardiña M, Otero A, Moyá A, Ríos MT, et al. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J. 2020 Dec;41(48):4565–76.
Group SR. Final report of a trial of intensive versus standard blood-pressure control. N Engl J Med. 2021;384(20):1921–30.
Juraschek SP, Appel LJ, Miller ER 3rd, Mukamal KJ, Lipsitz LA. Hypertension Treatment Effects on Orthostatic Hypotension and Its Relationship With Cardiovascular Disease. Hypertens (Dallas, Tex 1979). 2018 Oct;72(4):986–93.
Gautam V; Ramani MD; Patricia AU; et al. Chronic Heart Failure: Contemporary Diagnosis and Management. Mayo Clin Proc. 2010;85(2):180–95.
Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–67.
Krousel-Wood M, Joyce C, Holt E, Muntner P, Webber LS, Morisky DE, et al. Predictors of decline in medication adherence: results from the cohort study of medication adherence among older adults. Hypertension. 2011;58(5):804–10.
Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged≥ 75 years: a randomized clinical trial. Jama. 2016;315(24):2673–82.
Bonsu KO, Arunmanakul P, Chaiyakunapruk N. Pharmacological treatments for heart failure with preserved ejection fraction—a systematic review and indirect comparison. Heart Fail Rev. 2018;23:147–56.
Bruntol L, Dandan R, Knollmann B. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. Philadelphia: Mc Graw Hill Education; 2018.
Zipes D, Libby P, Bonow R. Braunwald’s Heart Disease. 8th ed. Philadelphia: Elsevier; 2019.
Rahimi K, Bidel Z, Nazarzadeh M, Copland E, Canoy D, Ramakrishnan R, et al. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet [Internet] 2021 May 1;397(10285):1625–36. Available from: https://doi.org/10.1016/S0140-6736(21)00590-0
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
